RAPP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Rapport Therapeutics Inc (RAPP) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock shows some technical bullishness and a positive analyst rating, the lack of significant trading trends, weak financial performance, and absence of recent news or strong catalysts make it prudent to hold off on investing right now.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram (0.234), indicating a potential upward trend. RSI is neutral at 55.069, suggesting no overbought or oversold conditions. Key support and resistance levels are Pivot: 29.061, R1: 31.005, and S1: 27.116.
Analyst from Wells Fargo initiated an Overweight rating with a $43 price target, citing 'best-in-category efficacy' potential in focal onset seizures.
Stock trend analysis suggests a 70% probability of a 6.27% increase over the next month.
No significant hedge fund or insider trading trends.
No recent news or event-driven catalysts.
Financials show no revenue and a net income loss of -$26.93M in Q3 2025, despite YoY improvement.
In Q3 2025, revenue remained at $0 with no YoY growth. Net income improved YoY by 53.53% to -$26.93M, and EPS improved by 42% to -0.71. Gross margin remains at 0.
Wells Fargo initiated coverage with an Overweight rating and a $43 price target, citing strong Phase 2a data and confidence in efficacy for focal onset seizures.
